JP2023527556A - 操作されたコロナウイルススパイク（ｓ）タンパク質およびその使用方法 - Google Patents

操作されたコロナウイルススパイク（ｓ）タンパク質およびその使用方法 Download PDF

Info

Publication number
JP2023527556A
JP2023527556A JP2022573585A JP2022573585A JP2023527556A JP 2023527556 A JP2023527556 A JP 2023527556A JP 2022573585 A JP2022573585 A JP 2022573585A JP 2022573585 A JP2022573585 A JP 2022573585A JP 2023527556 A JP2023527556 A JP 2023527556A
Authority
JP
Japan
Prior art keywords
engineered
protein
engineered protein
substitution
substitutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527556A5 (https=
Inventor
ジェーソン マクレラン
ジェニファー メイナード
アンドレア シャス
イリア フィンケルスタイン
モハマド ジャバンマルディ
ジェフリー ショーブ
ハン－チェ クオ
チア－ウェイ シュ
ジョリー ゴールドスミス
クリスティ ヒョース
チン－リン シエ
パトリック バーン
ニコル ジョンソン
ニアンシュアン ワン
ダニエル ラップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2023527556A publication Critical patent/JP2023527556A/ja
Publication of JP2023527556A5 publication Critical patent/JP2023527556A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022573585A 2020-05-29 2021-05-28 操作されたコロナウイルススパイク（ｓ）タンパク質およびその使用方法 Pending JP2023527556A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032502P 2020-05-29 2020-05-29
US63/032,502 2020-05-29
PCT/US2021/034713 WO2021243122A2 (en) 2020-05-29 2021-05-28 Engineered coronavirus spike (s) protein and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023527556A true JP2023527556A (ja) 2023-06-29
JP2023527556A5 JP2023527556A5 (https=) 2024-06-04

Family

ID=78722816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573585A Pending JP2023527556A (ja) 2020-05-29 2021-05-28 操作されたコロナウイルススパイク（ｓ）タンパク質およびその使用方法

Country Status (10)

Country Link
EP (1) EP4157345A4 (https=)
JP (1) JP2023527556A (https=)
KR (1) KR20230018394A (https=)
CN (1) CN116802193A (https=)
AU (1) AU2021279079A1 (https=)
BR (1) BR112022023591A2 (https=)
CA (1) CA3180554A1 (https=)
IL (1) IL298131A (https=)
MX (1) MX2022015040A (https=)
WO (1) WO2021243122A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012323782B2 (en) 2011-10-12 2017-04-06 Vaxxas Pty Limited Delivery device
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2023067193A2 (en) 2021-10-22 2023-04-27 BioNTech SE Compositions for administration of different doses of rna
US20250122546A1 (en) 2021-10-28 2025-04-17 BioNTech SE Rna constructs and uses thereof
AU2022398292A1 (en) 2021-11-29 2024-06-13 BioNTech SE Coronavirus vaccine
WO2023147091A1 (en) 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
WO2023196634A2 (en) * 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
EP4670167A1 (en) 2023-02-24 2025-12-31 BioNTech SE Systems and methods for modifying synthetic antigens to promote personalized immune responses
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
WO2024243641A1 (en) * 2023-06-02 2024-12-05 Vaxxas Pty Limited Covid vaccine delivered by hd-map
WO2024249848A2 (en) * 2023-06-02 2024-12-05 The Scripps Research Institute Coronavirus s2 immunogens
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
WO2025179238A2 (en) 2024-02-23 2025-08-28 BioNTech SE Coronavirus vaccine
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
WO2017037196A1 (en) * 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2020028902A1 (en) * 2018-08-03 2020-02-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nipah virus immunogens and their use
CN111088283A (zh) * 2020-03-20 2020-05-01 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
WO2017037196A1 (en) * 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2020028902A1 (en) * 2018-08-03 2020-02-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nipah virus immunogens and their use
CN111088283A (zh) * 2020-03-20 2020-05-01 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIORXIV PREPRINT DOI: HTTPS://DOI.ORG/10.1101/2020.05.18.102087, JPN6025027795, 18 May 2020 (2020-05-18), ISSN: 0005635287 *
DATABASE GENBANK [ONLINE], ACCESSIN NO. MN908947, JPN6025027796, 18 March 2020 (2020-03-18), ISSN: 0005635288 *

Also Published As

Publication number Publication date
KR20230018394A (ko) 2023-02-07
IL298131A (en) 2023-01-01
AU2021279079A1 (en) 2022-12-15
CN116802193A (zh) 2023-09-22
EP4157345A2 (en) 2023-04-05
CA3180554A1 (en) 2021-12-02
WO2021243122A3 (en) 2022-02-10
WO2021243122A2 (en) 2021-12-02
EP4157345A4 (en) 2024-09-11
US20230242594A1 (en) 2023-08-03
BR112022023591A2 (pt) 2022-12-27
MX2022015040A (es) 2023-02-27
WO2021243122A8 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
JP2023527556A (ja) 操作されたコロナウイルススパイク（ｓ）タンパク質およびその使用方法
JP7660671B2 (ja) 融合前安定化ｈｍｐｖ ｆタンパク質
US20240317810A1 (en) Prefusion-stabilized chimeric hmpv-rsv f proteins
EP4580671A2 (en) Prefusion-stabilized cmv gb proteins
WO2022241229A1 (en) Stabilized s2 beta-coronavirus antigens
US12617820B2 (en) Engineered coronavirus spike (s) protein and methods of use thereof
US12616747B2 (en) Stabilized beta-coronavirus antigens
US20230277653A1 (en) Stabilized beta-coronavirus antigens
JP2026503061A (ja) 融合前安定化ヒトパラインフルエンザウイルス３ｆタンパク質
WO2025171082A1 (en) Prefusion-stabilized hsv2 gb proteins
BR122024021506A2 (pt) Moléculas de ácido nucleico de proteína engenheirada compreendendo um ectodomínio de proteína f de metapneumovírus (mpv), e composiçao farmacêutica
BR122025014411A2 (pt) Molécula de ácido nucleico e composição farmacêutica que compreende a mesma
WO2025212898A1 (en) Pre-fusion stabilized cchfv gp38-gn-gc glycoprotein complex

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260212